10 results on '"Rust, Alistair G."'
Search Results
2. Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression.
- Author
-
Rangel, Roberto, Guzman-Rojas, Liliana, Mann, Michael B., Newberg, Justin Y., Takahiro Kodama, Jenkins, Nancy A., Copeland, Neal G., Song-Choon Lee, Ward, Jerrold M., Chin, Kuan-Yew, Hon-Kim Ban, Kenneth, McNoe, Leslie A., Selvanesan, Luxmanan, Black, Michael A., and Rust, Alistair G.
- Subjects
TRANSPOSONS ,MUTAGENESIS ,GENES ,BREAST cancer research ,PTEN protein - Abstract
Triple-negative breast cancer (TNBC) has the worst prognosis of any breast cancer subtype. To better understand the genetic forces driving TNBC, we performed a transposon mutagenesis screen in a phosphatase and tensin homolog (Pten) mutant mice and identified 12 candidate trunk drivers and a much larger number of progression genes. Validation studies identified eight TNBC tumor suppressor genes, including the GATA-like transcriptional repressor TRPS1. Down-regulation of TRPS1 in TNBC cells promoted epithelial-to-mesenchymal transition (EMT) by deregulating multiple EMT pathway genes, in addition to increasing the expression of SERPINE1 and SERPINB2 and the subsequent migration, invasion, and metastasis of tumor cells. Transposon mutagenesis has thus provided a better understanding of the genetic forces driving TNBC and discovered genes with potential clinical importance in TNBC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Sleeping Beauty transposon mutagenesis identifies genes that cooperate with mutant Smad4 in gastric cancer development.
- Author
-
Haruna Takeda, Rust, Alistair G., Ward, Jerrold M., Chin Kuan Yew, Christopher, Jenkins, Nancy A., and Copeland, Neal G.
- Subjects
- *
GASTROINTESTINAL cancer , *CANCER research , *TRANSPOSONS , *MUTAGENESIS , *PROTEOLYSIS - Abstract
Mutations in SMAD4 predispose to the development of gastrointestinal cancer, which is the third leading cause of cancer-related deaths. To identify genes driving gastric cancer (GC) development, we performed a Sleeping Beauty (SB) transposon mutagenesis screen in the stomach of Smad4+/- mutant mice. This screen identified 59 candidate GC trunk drivers and a much larger number of candidate GC progression genes. Strikingly, 22 SB-identified trunk drivers are known or candidate cancer genes, whereas four SB-identified trunk drivers, including PTEN, SMAD4, RNF43, and NF1, are known human GC trunk drivers. Similar to human GC, pathway analyses identified WNT, TGF-β, and PI3K-PTEN signaling, ubiquitin- mediated proteolysis, adherens junctions, and RNA degradation in addition to genes involved in chromatin modification and organization as highly deregulated pathways in GC. Comparative oncogenomic filtering of the complete list of SB-identified genes showed that they are highly enriched for genes mutated in human GC and identified many candidate human GC genes. Finally, by comparing our complete list of SB-identified genes against the list of mutated genes identified in five large-scale human GC sequencing studies, we identified LDL receptor-related protein 1B (LRP1B) as a previously unidentified human candidate GC tumor suppressor gene. In LRP1B, 129 mutations were found in 462 human GC samples sequenced, and LRP1B is one of the top 10 most deleted genes identified in a panel of 3,312 human cancers. SB mutagenesis has, thus, helped to catalog the cooperative molecular mechanisms driving SMAD4-induced GC growth and discover genes with potential clinical importance in human GC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5+/- leukemia.
- Author
-
van der Weyden, Louise, Giotopoulos, George, Kim Wong, Rust, Alistair G., Robles-Espinoza, Carla Daniela, Hikari Osaki, Huntly, Brian J., and Adams, David J.
- Subjects
LYMPHOBLASTIC leukemia in children ,CANCER-related mortality ,B cells ,CHROMOSOME abnormalities ,MUTAGENESIS ,TRANSPOSONS ,DIAGNOSIS - Abstract
Background: B-cell precursor acute lymphoblastic leukemia (B-ALL) is amongst the leading causes of childhood cancer-related mortality. Its most common chromosomal aberration is the ETV6-RUNX1 fusion gene, with ~25% of ETV6-RUNX1 patients also carrying PAX5 alterations. Methods: We have recreated this mutation background by inter-crossing Etv6-RUNX1 (Etv6
RUNX1-SB ) and Pax5+/- mice and performed an in vivo analysis to find driver genes using Sleeping Beauty transposon-mediated mutagenesis and also exome sequencing. Results: Combination of Etv6-RUNX1 and Pax5+/- alleles generated a transplantable B220 + CD19+ B-ALL with a significant disease incidence. RNA-seq analysis showed a gene expression pattern consistent with arrest at the pre-B stage. Analysis of the transposon common insertion sites identified genes involved in B-cell development (Zfp423) and the JAK/STAT signaling pathway (Jak1, Stat5 and Il2rb), while exome sequencing revealed somatic hotspot mutations in Jak1 and Jak3 at residues analogous to those mutated in human leukemias, and also mutation of Trp53. Conclusions: Powerful synergies exists in our model suggesting STAT pathway activation and mutation of Trp53 are potent drivers of B-ALL in the context of Etv6-RUNX1;Pax5+/- . [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
5. Transposon mutagenesis identifies genetic drivers of BrafV600E melanoma.
- Author
-
Mann, Michael B, Copeland, Neal G, Jenkins, Nancy A, Black, Michael A, Jones, Devin J, Newberg, Justin Y, Ward, Jerrold M, Yew, Christopher Chin Kuan, Dupuy, Adam J, Rust, Alistair G, Bosenberg, Marcus W, McMahon, Martin, and Print, Cristin G
- Subjects
TRANSPOSONS ,MUTAGENESIS ,MELANOGENESIS ,ONCOGENIC DNA viruses ,NETRINS - Abstract
Although nearly half of human melanomas harbor oncogenic BRAF
V600E mutations, the genetic events that cooperate with these mutations to drive melanogenesis are still largely unknown. Here we show that Sleeping Beauty (SB) transposon-mediated mutagenesis drives melanoma progression in BrafV600E mutant mice and identify 1,232 recurrently mutated candidate cancer genes (CCGs) from 70 SB-driven melanomas. CCGs are enriched in Wnt, PI3K, MAPK and netrin signaling pathway components and are more highly connected to one another than predicted by chance, indicating that SB targets cooperative genetic networks in melanoma. Human orthologs of >500 CCGs are enriched for mutations in human melanoma or showed statistically significant clinical associations between RNA abundance and survival of patients with metastatic melanoma. We also functionally validate CEP350 as a new tumor-suppressor gene in human melanoma. SB mutagenesis has thus helped to catalog the cooperative molecular mechanisms driving BRAFV600E melanoma and discover new genes with potential clinical importance in human melanoma. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
6. Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression.
- Author
-
Takeda, Haruna, Yew, Christopher Chin Kuan, Mann, Michael B, Jenkins, Nancy A, Rust, Alistair G, Adams, David J, Copeland, Neal G, Koso, Hideto, Wei, Zhubo, and Ward, Jerrold M
- Subjects
TRANSPOSONS ,MUTAGENESIS ,GASTROINTESTINAL diseases ,TUMORS ,GENETICS ,MICROBIAL mutation - Abstract
To provide a more comprehensive understanding of the genes and evolutionary forces driving colorectal cancer (CRC) progression, we performed Sleeping Beauty (SB) transposon mutagenesis screens in mice carrying sensitizing mutations in genes that act at different stages of tumor progression. This approach allowed us to identify a set of genes that appear to be highly relevant for CRC and to provide a better understanding of the evolutionary forces and systems properties of CRC. We also identified six genes driving malignant tumor progression and a new human CRC tumor-suppressor gene, ZNF292, that might also function in other types of cancer. Our comprehensive CRC data set provides a resource with which to develop new therapies for treating CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. Chromatin Landscapes of Retroviral and Transposon Integration Profiles.
- Author
-
de Jong, Johann, Akhtar, Waseem, Badhai, Jitendra, Rust, Alistair G., Rad, Roland, Hilkens, John, Berns, Anton, van Lohuizen, Maarten, Wessels, Lodewyk F. A., and de Ridder, Jeroen
- Subjects
RETROVIRUS genetics ,TRANSPOSONS ,MOLECULAR biology ,CANCER research ,GENE therapy ,CANCER genes ,CANCER genetics - Abstract
The ability of retroviruses and transposons to insert their genetic material into host DNA makes them widely used tools in molecular biology, cancer research and gene therapy. However, these systems have biases that may strongly affect research outcomes. To address this issue, we generated very large datasets consisting of to unselected integrations in the mouse genome for the Sleeping Beauty (SB) and piggyBac (PB) transposons, and the Mouse Mammary Tumor Virus (MMTV). We analyzed (epi)genomic features to generate bias maps at both local and genome-wide scales. MMTV showed a remarkably uniform distribution of integrations across the genome. More distinct preferences were observed for the two transposons, with PB showing remarkable resemblance to bias profiles of the Murine Leukemia Virus. Furthermore, we present a model where target site selection is directed at multiple scales. At a large scale, target site selection is similar across systems, and defined by domain-oriented features, namely expression of proximal genes, proximity to CpG islands and to genic features, chromatin compaction and replication timing. Notable differences between the systems are mainly observed at smaller scales, and are directed by a diverse range of features. To study the effect of these biases on integration sites occupied under selective pressure, we turned to insertional mutagenesis (IM) screens. In IM screens, putative cancer genes are identified by finding frequently targeted genomic regions, or Common Integration Sites (CISs). Within three recently completed IM screens, we identified 7%–33% putative false positive CISs, which are likely not the result of the oncogenic selection process. Moreover, results indicate that PB, compared to SB, is more suited to tag oncogenes. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
8. Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model.
- Author
-
Bard-Chapeau, Emilie A, Nguyen, Anh-Tuan, Rust, Alistair G, Sayadi, Ahmed, Lee, Philip, Chua, Belinda Q, New, Lee-Sun, de Jong, Johann, Ward, Jerrold M, Chin, Christopher K Y, Chew, Valerie, Toh, Han Chong, Abastado, Jean-Pierre, Benoukraf, Touati, Soong, Richie, Bard, Frederic A, Dupuy, Adam J, Johnson, Randy L, Radda, George K, and Chan, Eric Chun Yong
- Subjects
TRANSPOSONS ,HEPATITIS B ,LABORATORY mice ,MUTAGENESIS ,LIVER cancer ,GENETIC regulation - Abstract
The most common risk factor for developing hepatocellular carcinoma (HCC) is chronic infection with hepatitis B virus (HBV). To better understand the evolutionary forces driving HCC, we performed a near-saturating transposon mutagenesis screen in a mouse HBV model of HCC. This screen identified 21 candidate early stage drivers and a very large number (2,860) of candidate later stage drivers that were enriched for genes that are mutated, deregulated or functioning in signaling pathways important for human HCC, with a striking 1,199 genes being linked to cellular metabolic processes. Our study provides a comprehensive overview of the genetic landscape of HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells.
- Author
-
Koso, Hideto, Takeda, Haruna, Kuan Yewa, Christopher Chin, Ward, Jerrold M., Nariai, Naoki, Ueno, Kazuko, Nagasaki, Masao, Watanabe, Sumiko, Rust, Alistair G., Adams, David J., Copeland, Neal G., and Jenkins, Nancy A.
- Subjects
TRANSPOSONS ,MUTAGENESIS ,NEURAL stem cells ,GLIOMAS ,CANCER cells ,TUMORS - Abstract
In this article, the authors discuss the role of transposon mutagenesis in identifying genes that transform neural stem cells (NSCs) into glioma-initiating cells (GC). They mention a study which used transposans to identify genes and signaling pathways to transform NSCs into cancer initiating cells (CIC) for GC. The study also examined the combinations of CIS genes in tumors derived from a single immortalized line.
- Published
- 2012
- Full Text
- View/download PDF
10. Loss of Rassf1a Synergizes with Deregulated Runx2 Signaling in Tumorigenesis.
- Author
-
van der Weyden, Louise, Papaspyropoulos, Angelos, Poulogiannis, George, Rust, Alistair G., Rashid, Mamunur, Adams, David J., Arends, Mark J., and O'Neill, Eric
- Subjects
- *
CARCINOGENESIS , *TUMOR suppressor genes , *GENETIC mutation , *CANCER , *TRANSPOSONS , *MUTAGENESIS - Abstract
The tumor suppressor gene RASSF1A is inactivated through point mutation or promoter hypermethylation in many human cancers. In this study, we conducted a Sleeping Beauty transposon-mediated insertional mutagenesis screen in Rassf1a-null mice to identify candidate genes that collaborate with loss of Rassf1a in tumorigenesis. We identified 10 genes, including the transcription factor Runx2, a transcriptional partner of Yes-associated protein (YAP1) that displays tumor suppressive activity through competing with the oncogenic TEA domain family of transcription factors (TEAD) for YAP1 association. While loss of RASSF1A promoted the formation of oncogenic YAP1-TEAD complexes, the combined loss of both RASSF1A and RUNX2 further increased YAP1-TEAD levels, showing that loss of RASSF1A, together with RUNX2, is consistent with the multistep model of tumorigenesis. Clinically, RUNX2 expression was frequently downregulated in various cancers, and reduced RUNX2 expression was associated with poor survival in patients with diffuse large B-cell or atypical Burkitt/Burkitt-like lymphomas. Interestingly, decreased expression levels of RASSF1 and RUNX2 were observed in both precursor T-cell acute lymphoblastic leukemia and colorectal cancer, further supporting the hypothesis that dual regulation of YAP1-TEAD promotes oncogenic activity. Together, our findings provide evidence that loss of RASSF1A expression switches YAP1 from a tumor suppressor to an oncogene through regulating its association with transcription factors, thereby suggesting a novel mechanism for RASSF1A-mediated tumor suppression. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.